Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages.
Amphotericin B derivatives, such as MS-8209, have been evaluated as a therapeutic approach to human immunodeficiency virus (HIV) infection. We show that MS-8209, like amphotericin B, increases tumor necrosis factor alpha (TNF-alpha) mRNA expression and TNF-alpha production and consequently HIV replication in human macrophages. These effects confirm the pharmacological risk associated with the administration of amphotericin B or its derivatives to HIV-infected patients.
Clayette
P
P
CEA, Service de Neurovirologie, DSV/DRM, CRSSA, IPSC, Fontenay aux Roses, Paris, France. clayette@dsvidf.cea.fr
Martin
M
M
Beringue
V
V
Dereuddre-Bosquet
N
N
Adjou
K T
KT
Seman
M
M
Dormont
D
D
D000666:Amphotericin B / Q000031:analogs & derivatives* / Q000494:pharmacology; D019380:Anti-HIV Agents / Q000494:pharmacology*; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008264:Macrophages / Q000378:metabolism / Q000821:virology*; D012333:RNA, Messenger / Q000096:biosynthesis; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; C074660:MS 8209; D000666:Amphotericin B